Navigation Links
Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
Date:7/20/2009

l pharmacokinetic studies and the positive results from its North American Phase III placebo-controlled clinical trial (study 04ACL3-001), which enrolled more than 400 patients. The results of this study are found in the May 2009 issue of Psychiatry (Edgemont) (Volume 6, Number 5) (www.psychiatrymmc.com).

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these f
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ... procedures and executing them with care and precision. There is an art and ... has had the honor of successfully reshaping the facial features and lives of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Scientists at the University ... through five federal grants to study a group of related mosquito-borne viruses. The ... , The research will be conducted in the Regional Biocontainment Laboratory (RBL) at ...
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, ... retained to lead a national chief executive officer recruitment for Indiana ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of the Gelatin Capsule manufacturers. The report is a valuable source of guidance ... depicts the global and Chinese market for the Gelatin Capsule industry including capacity, ...
(Date:7/2/2015)... Mobile, AL (PRWEB) , ... July 02, 2015 , ... Every year, DUI arrests and ... of July may be the deadliest day of the year when it comes to being ... , “The National Highway Traffic Safety Association reports that 40% of all highway deaths between ...
Breaking Medicine News(10 mins):Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:Attorney David Maloney Stresses Safety through Sobriety 2
... with depression, bipolar disorders could receive more targeted treatment ... types of imaging techniques enable researchers to map brain ... in depression, bipolar disorder and other mood disorders, and ... these techniques was expected to be presented Tuesday during ...
... to Secondhand Smoke,in the Nation,s Capitol, Statement of ... 6 On behalf of the American,Lung Association, I ... (D-OH), Dick Durbin (D-IL) and Jack Reed (D-RI) for,their ... in the,Senate. For too long, Senators, staff and visitors ...
... XM Satellite Radio announced today,the second annual ... Sam,s Club raise $10 million in May for ... and improving the,lives of children at hospitals across ... The XMKiDS Traveling Roadshow will kick-off on ...
... France, May 6 NicOx S.A.,(Euronext Paris: COX) ... 2 study,conducted by its partner Pfizer Inc, which ... PF-03187207 to Xalatan(R) (latanoprost) 0.005% in,patients with primary ... PF-03187207 demonstrated a clinically significant reduction,in diurnal intraocular ...
... into melanoma by showing the interaction of two key ... Penn State scientists also demonstrate that therapeutic targeting of ... this deadly form of cancer. , "We have shown ... communicate with one another in a mole, they cooperate ...
... Health Inc. (TSX: DAX),(Nasdaq: DRAX ) will report ... Friday May 9, 2008., Annual and Special Meeting ... "Meeting") of shareholders of,DRAXIS is scheduled to be held ... Bank Tower, Toronto, Ontario, Canada on Friday, May 23, ...
Cached Medicine News:Health News:Imaging Advances Map Brain Areas Affecting Mood 2Health News:Imaging Advances Map Brain Areas Affecting Mood 3Health News:American Lung Association Hails Decision to Snuff Out Smoking in U.S. Senate Lounges 2Health News:XM Launches Second Annual 'XMKiDS Traveling Roadshow' National Initiative Benefiting Children's Miracle Network 2Health News:XM Launches Second Annual 'XMKiDS Traveling Roadshow' National Initiative Benefiting Children's Miracle Network 3Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 2Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 3Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 4Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 5Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 6Health News:Scientists identify interacting proteins key to melanoma development, treatment 2Health News:Scientists identify interacting proteins key to melanoma development, treatment 3Health News:DRAXIS to Report First Quarter Results on May 9th 2Health News:DRAXIS to Report First Quarter Results on May 9th 3Health News:DRAXIS to Report First Quarter Results on May 9th 4
(Date:7/2/2015)... TOKYO , July 2, 2015  Konica Minolta, ... today announced that it has acquired Sawae Technologica Ltda., ... Brazil , through its Brazilian healthcare ... . Local Brazil ... increasing population exceeding 200 million, significant healthcare ...
(Date:7/2/2015)... South Korea, July 2, 2015 ALPINION MEDICAL SYSTEMS ... E-CUBE Series ultrasound system. Developed to enhance user experience ... the E-CUBE 15 EX produces superb image quality. With ... in women,s health, general imaging, and shared service applications. ... latest in the renowned E-CUBE Series, the E-CUBE 15 ...
(Date:7/2/2015)... July 2, 2015   Wilson Therapeutics AB , ... Hans Schikan to its board of directors. The appointment ... Meeting on June 30. "We are delighted ... Jonas Hansson , CEO of Wilson Therapeutics. "Hans ... we look forward to his contributions to the Company." ...
Breaking Medicine Technology:Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 3Wilson Therapeutics Appoints Hans Schikan to its Board of Directors 2
... WALTHAM, Mass., Sept. 23 Interleukin Genetics, ... top-line positive results from a retrospective clinical study on ... study previously reported in the Journal of the American ... following diets matched to their genotype, as determined by ...
... , , NOVATO, Calif., Sept. ... today that the first patient has initiated treatment in the Phase ... the treatment of phenylketonuria (PKU). Initial top-line results are expected in ... program and believe that, if approved, PEG-PAL may offer a significant ...
Cached Medicine Technology:Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Test's Impact on Weight Loss 2Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Test's Impact on Weight Loss 3BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU 2BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU 3
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
... Tip flattened and angled 90 1.0mm from end, ... lock high pressure extension tubing set, Capable of ... OD- 1.5mm (.06 in) long luer lock, high ... tubing. Bend 1.0mm from end. (Cannulas ...
Rounded tip for even incisions reducing post-op astigmatism...
Stab incision blades color coded for simple and accurate identification...
Medicine Products: